Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis

Abstract Ocular surface inflammation due to allergy and blepharitis can lead to corneal complications and visual impairment. The aim of this study is to evaluate the efficacy of a cyclosporin 0.1% topical treatment achieving steroid-sparing. Eighty pediatric patients with moderate and severe vernal...

Full description

Saved in:
Bibliographic Details
Main Authors: Amarilla Barcsay-Veres, Anita Csorba, Illes Kovacs, Laszlo Tothfalusi, Otto Alexander Maneschg
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-85256-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823862272727973888
author Amarilla Barcsay-Veres
Anita Csorba
Illes Kovacs
Laszlo Tothfalusi
Otto Alexander Maneschg
author_facet Amarilla Barcsay-Veres
Anita Csorba
Illes Kovacs
Laszlo Tothfalusi
Otto Alexander Maneschg
author_sort Amarilla Barcsay-Veres
collection DOAJ
description Abstract Ocular surface inflammation due to allergy and blepharitis can lead to corneal complications and visual impairment. The aim of this study is to evaluate the efficacy of a cyclosporin 0.1% topical treatment achieving steroid-sparing. Eighty pediatric patients with moderate and severe vernal and blepharitis-related keratoconjunctivitis were included. Symptoms (photosensitivity, itching, discharge, tearing), signs (corneal fluorescein staining, papillary hypertrophy) and patients’ subjective assessment were evaluated during a 6-month follow-up. At the follow-up, all patients treated with topical cyclosporin showed a significant improvement in all subjective symptoms and objective signs (p < 0.001). The total number of courses of rescue steroids courses decreased from 3.71 ± 1.72 to 0.25 ± 0.49 at month 3 and to 0.13 ± 0.38 dropping bottle at month 6 (p < 0.001 at both time points). The 96.1% of the allergic cohort and 96.4% of the blepharitis cohort experienced a satisfactory good or rapid and good effect during the 6-month follow-up. The probability of needing rescue corticosteroids increased with an odds ratio of 1.98, (95% CI: 1.19–3.28, p = 0.008) for each unit increase in Oxford score when analysing the whole cohort. Topical cyclosporin seems to be very effective reducing the number of recurrences of corneal involvement and the need for steroid treatment.
format Article
id doaj-art-fd90b767e2944786a8316f38e1c606ff
institution Kabale University
issn 2045-2322
language English
publishDate 2025-02-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-fd90b767e2944786a8316f38e1c606ff2025-02-09T12:36:59ZengNature PortfolioScientific Reports2045-23222025-02-011511910.1038/s41598-025-85256-zCorticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitisAmarilla Barcsay-Veres0Anita Csorba1Illes Kovacs2Laszlo Tothfalusi3Otto Alexander Maneschg4Department of Ophthalmology, Semmelweis UniversityDepartment of Ophthalmology, Semmelweis UniversityDepartment of Ophthalmology, Semmelweis UniversityDepartment of Pharmacodynamics, Semmelweis UniversityDepartment of Ophthalmology, Semmelweis UniversityAbstract Ocular surface inflammation due to allergy and blepharitis can lead to corneal complications and visual impairment. The aim of this study is to evaluate the efficacy of a cyclosporin 0.1% topical treatment achieving steroid-sparing. Eighty pediatric patients with moderate and severe vernal and blepharitis-related keratoconjunctivitis were included. Symptoms (photosensitivity, itching, discharge, tearing), signs (corneal fluorescein staining, papillary hypertrophy) and patients’ subjective assessment were evaluated during a 6-month follow-up. At the follow-up, all patients treated with topical cyclosporin showed a significant improvement in all subjective symptoms and objective signs (p < 0.001). The total number of courses of rescue steroids courses decreased from 3.71 ± 1.72 to 0.25 ± 0.49 at month 3 and to 0.13 ± 0.38 dropping bottle at month 6 (p < 0.001 at both time points). The 96.1% of the allergic cohort and 96.4% of the blepharitis cohort experienced a satisfactory good or rapid and good effect during the 6-month follow-up. The probability of needing rescue corticosteroids increased with an odds ratio of 1.98, (95% CI: 1.19–3.28, p = 0.008) for each unit increase in Oxford score when analysing the whole cohort. Topical cyclosporin seems to be very effective reducing the number of recurrences of corneal involvement and the need for steroid treatment.https://doi.org/10.1038/s41598-025-85256-zVernal keratoconjunctivitisBlepharokeratoconjunctivitisCyclosporinCorneal fluorescein stainingSteroid-sparing
spellingShingle Amarilla Barcsay-Veres
Anita Csorba
Illes Kovacs
Laszlo Tothfalusi
Otto Alexander Maneschg
Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
Scientific Reports
Vernal keratoconjunctivitis
Blepharokeratoconjunctivitis
Cyclosporin
Corneal fluorescein staining
Steroid-sparing
title Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
title_full Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
title_fullStr Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
title_full_unstemmed Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
title_short Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
title_sort corticosteroid sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
topic Vernal keratoconjunctivitis
Blepharokeratoconjunctivitis
Cyclosporin
Corneal fluorescein staining
Steroid-sparing
url https://doi.org/10.1038/s41598-025-85256-z
work_keys_str_mv AT amarillabarcsayveres corticosteroidsparingtopicaltreatmentwithcyclosporinforjuvenilekeratoconjunctivitis
AT anitacsorba corticosteroidsparingtopicaltreatmentwithcyclosporinforjuvenilekeratoconjunctivitis
AT illeskovacs corticosteroidsparingtopicaltreatmentwithcyclosporinforjuvenilekeratoconjunctivitis
AT laszlotothfalusi corticosteroidsparingtopicaltreatmentwithcyclosporinforjuvenilekeratoconjunctivitis
AT ottoalexandermaneschg corticosteroidsparingtopicaltreatmentwithcyclosporinforjuvenilekeratoconjunctivitis